Genmab AS

GMAB: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|N<BLOCK|%G<nmLOCK|w&xg?@

Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook

Genmab reported first-quarter revenue of $896 million, a 25% increase year over year. Operating profit growth was 23%, excluding the impact of acquisition and integration-related charges tied to the Merus acquisition and amortization of acquired assets. Management maintained its 2026 guidance.

Sponsor Center